Ann: Quarterly Activity Report & Appendix 4C - 30 September 2020, page-19

no, none of this report shows the extra capacity...to be precise it doesn't show they have sold all the extra capacity already in play for Sept'20 (which is when it was to hit 750k)...so each month now they have double the capacity from FY20...and that is expected to translate into sales to NGBio pending amt/AccBio US supply/Divoc India supply + AT1's AU supply + HIV supply (whatever that is)..

So yes, Q2-Q3 should show exponential sales/revenue growth..and then double again with the capacity increase...but this is still dependant on those additional large market approvals + orders coming in. No clarity (for us without internal company view) which Qtr orders will drive up.